Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer’s Disease

[1]  J. Morris,et al.  Associations Between &bgr;-Amyloid Kinetics and the &bgr;-Amyloid Diurnal Pattern in the Central Nervous System , 2017, JAMA neurology.

[2]  N. Nalivaeva,et al.  Role of Ageing and Oxidative Stress in Regulation of Amyloid-Degrading Enzymes and Development of Neurodegeneration. , 2017, Current aging science.

[3]  D. Muresanu,et al.  Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy. , 2016, Neurodegenerative disease management.

[4]  J. Lafuente,et al.  Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair. , 2016, CNS & neurological disorders drug targets.

[5]  R. Tuan,et al.  Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies , 2016, Stem Cell Research & Therapy.

[6]  T. Hyeon,et al.  Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer's Disease. , 2016, ACS nano.

[7]  Bin Ji,et al.  Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. , 2016, Biomaterials.

[8]  L. Tan,et al.  Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy , 2015, Molecular Neurobiology.

[9]  Bengt Winblad,et al.  Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice , 2015, Proteomics.

[10]  Junqing Wang,et al.  Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease , 2015, Journal of neuroscience research.

[11]  H. Tomioka,et al.  Beyond the Hypothesis of Serum Anticholinergic Activity in Alzheimer's Disease: Acetylcholine Neuronal Activity Modulates Brain-Derived Neurotrophic Factor Production and Inflammation in the Brain , 2015, Neurodegenerative Diseases.

[12]  K. Blennow,et al.  Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[13]  L. Lue,et al.  p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease , 2015, Molecular Psychiatry.

[14]  Yuan Chen,et al.  Brain-Derived Neurotrophic Factor Ameliorates Learning Deficits in a Rat Model of Alzheimer's Disease Induced by Aβ1-42 , 2015, PloS one.

[15]  J. Lafuente,et al.  TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches , 2015 .

[16]  R. Bateman,et al.  Amyloid‐β efflux from the central nervous system into the plasma , 2014, Annals of neurology.

[17]  Xiaoyao Zheng,et al.  The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[18]  H. Kim,et al.  Carbon nanotube-collagen three-dimensional culture of mesenchymal stem cells promotes expression of neural phenotypes and secretion of neurotrophic factors. , 2014, Acta biomaterialia.

[19]  L. Calzà,et al.  Human Mesenchymal Stem Cells Produce Bioactive Neurotrophic Factors: Source, Individual Variability and Differentiation Issues , 2014, International journal of immunopathology and pharmacology.

[20]  R. Marr,et al.  Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance , 2014, Front. Aging Neurosci..

[21]  C. Martínez-Cué,et al.  Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease , 2014, Neuroscience.

[22]  Jong-sang Park,et al.  Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice , 2013, Brain Research.

[23]  Fabienne Aujard,et al.  Animal models of Alzheimer's disease and drug development. , 2013, Drug discovery today. Technologies.

[24]  Shaonan Yang,et al.  Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse model , 2013, Stem Cell Research & Therapy.

[25]  Agneta Nordberg,et al.  Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. , 2013, Brain : a journal of neurology.

[26]  K. Takagaki,et al.  Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes , 2013, Scientific Reports.

[27]  E. Masliah,et al.  Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease , 2013, Journal of neuroscience research.

[28]  C. Masters,et al.  The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation. , 2012, Current Alzheimer research.

[29]  Bojana Stefanovic,et al.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. , 2012, Brain : a journal of neurology.

[30]  A. Cattaneo,et al.  Nerve Growth Factor and Alzheimer's Disease: New Facts for an Old Hypothesis , 2012, Molecular Neurobiology.

[31]  D. Muresanu,et al.  Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. , 2012, CNS & neurological disorders drug targets.

[32]  T. Lundstedt,et al.  Nanowired drug delivery to enhance neuroprotection in spinal cord injury. , 2012, CNS & neurological disorders drug targets.

[33]  D. Na,et al.  Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques , 2011, Cell Death and Differentiation.

[34]  D. Van Dam,et al.  Animal models in the drug discovery pipeline for Alzheimer's disease , 2011, British journal of pharmacology.

[35]  B. Diniz,et al.  Brain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond , 2011, NeuroMolecular Medicine.

[36]  N. Zawia,et al.  In vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysin. , 2011, Neurotoxicology.

[37]  K. Alzoubi,et al.  Impaired neural transmission and synaptic plasticity in superior cervical ganglia from β-amyloid rat model of Alzheimer's disease. , 2011, Current Alzheimer research.

[38]  S. Love,et al.  Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β. , 2011, Journal of Alzheimer's disease : JAD.

[39]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[40]  A. Ludolph,et al.  Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells. , 2010, Stem cells and development.

[41]  Roger M. Nitsch,et al.  The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. , 2010, Journal of molecular biology.

[42]  Jian Huang,et al.  Estrogen Stimulates Degradation of β-Amyloid Peptide by Up-regulating Neprilysin* , 2009, The Journal of Biological Chemistry.

[43]  H. Krämer,et al.  Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase , 2009, Neurobiology of Disease.

[44]  E. Kiyatkin,et al.  Permeability of the blood–brain barrier depends on brain temperature , 2009, Neuroscience.

[45]  Xiaoyan Hu,et al.  Ginsenoside Rg3 promotes beta‐amyloid peptide degradation by enhancing gene expression of neprilysin , 2009 .

[46]  L. Mucke,et al.  Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic Aβ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice , 2009, The Journal of Neuroscience.

[47]  E. Kiyatkin,et al.  Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: An experimental study using light and electron microscopy , 2009, Journal of Chemical Neuroanatomy.

[48]  I. Hakker,et al.  Overexpression of Neprilysin Reduces Alzheimer Amyloid-β42 (Aβ42)-induced Neuron Loss and Intraneuronal Aβ42 Deposits but Causes a Reduction in cAMP-responsive Element-binding Protein-mediated Transcription, Age-dependent Axon Pathology, and Premature Death in Drosophila* , 2008, Journal of Biological Chemistry.

[49]  I. Verma,et al.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.

[50]  N. Belyaev,et al.  Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.

[51]  L. Hersh,et al.  Neprilysin and amyloid beta peptide degradation. , 2008, Current Alzheimer research.

[52]  S. Love,et al.  Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid , 2008, Journal of Neuroscience Methods.

[53]  C. Duyckaerts,et al.  Alzheimer disease models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.

[54]  J. Frackowiak,et al.  Neprilysin protects human neuronal progenitor cells against impaired development caused by amyloid-β peptide , 2006, Brain Research.

[55]  A. Caplan,et al.  Mesenchymal stem cells as trophic mediators , 2006, Journal of cellular biochemistry.

[56]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[57]  H. Buschke,et al.  Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. , 2005, Journal of neuropathology and experimental neurology.

[58]  M. Marcinkiewicz,et al.  Declining Expression of Neprilysin in Alzheimer Disease Vasculature: Possible Involvement in Cerebral Amyloid Angiopathy , 2002, Journal of neuropathology and experimental neurology.

[59]  T. Nabeshima,et al.  Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. , 2000, Pharmacology & therapeutics.

[60]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[61]  J. Westman,et al.  Acute systemic heat stress increases glial fibrillary acidic protein immunoreactivity in brain: Experimental observations in conscious normotensive young rats , 1992, Neuroscience.

[62]  P. K. Dey,et al.  Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats , 1990, Brain Research.

[63]  Y. Olsson,et al.  Effects of p-chlorophenylalanine on microvascular permeability changes in spinal cord trauma , 1990, Acta Neuropathologica.

[64]  P. K. Dey,et al.  Influence of long-term immobilization stress on regional blood-brain barrier permeability, cerebral blood flow and 5-HT level in conscious normotensive young rats , 1986, Journal of the Neurological Sciences.

[65]  H. Jasper,et al.  Measurement of experimentally induced brain swelling and shrinkage. , 1949, The American journal of physiology.

[66]  R. Dean,et al.  Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies. , 2015, Journal of Alzheimer's disease : JAD.

[67]  F. Sengpiel,et al.  Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[68]  N. Jha,et al.  Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. , 2015, Journal of Alzheimer's disease : JAD.

[69]  T. Bayer,et al.  Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[70]  Harald Hampel,et al.  Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[71]  S. Schmidt,et al.  Aβ measurement by enzyme-linked immunosorbent assay. , 2012, Methods in molecular biology.

[72]  R. Castellani,et al.  The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. , 2012, International review of neurobiology.

[73]  L. Wiklund,et al.  Cardiac arrest-induced regional blood–brain barrier breakdown, edema formation and brain pathology: a light and electron microscopic study on a new model for neurodegeneration and neuroprotection in porcine brain , 2010, Journal of Neural Transmission.

[74]  S. Schmidt,et al.  ELISA method for measurement of amyloid-beta levels. , 2005, Methods in molecular biology.

[75]  S. Schmidt,et al.  ELISA Method for Measurement of Amyloid-ß Levels , 2005 .

[76]  Y. Olsson,et al.  Early perifocal cell changes and edema in traumatic injury of the spinal cord are reduced by indomethacin, an inhibitor of prostaglandin synthesis , 2004, Acta Neuropathologica.

[77]  Y. Olsson,et al.  Trauma-induced opening of the the blood-spinal cord barrier is reduced by indomethacin, an inhibitor of prostaglandin biosynthesis. Experimental observations in the rat using [131I]-sodium, Evans blue and lanthanum as tracers. , 1995, Restorative neurology and neuroscience.

[78]  J. Cervós-Navarro,et al.  Brain oedema and cellular changes induced by acute heat stress in young rats. , 1990, Acta neurochirurgica. Supplementum.